[Federal Register Volume 62, Number 171 (Thursday, September 4, 1997)]
[Notices]
[Pages 46750-46751]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-23383]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Workshop on Thalidomide: Potential Benefits and Risks
Notice is hereby given of the NIH workshop on ``Thalidomide:
Potential Benefits and Risks,'' which will be held September 9-10,
1997, in the Natcher Conference Center of the National Institutes of
Health, 9000 Rockville Pike, Bethesda, Maryland 20892. The conference
begins at 8:30 a.m. on September 9 and at 8 a.m. on September 10.
Thalidomide was associated in 1961 with serious human
teratogenicity. Its use in the treatment of morning sickness
[[Page 46751]]
and insomnia was abandoned, and it became infamous as an example of a
drug with major toxic effects. Thalidomide is now being studied as a
treatment for many serious diseases, including erythema nodosum
leprosum, chronic graft-versus-host disease, and aphthous ulcers in
patients with and without HIV infection.
The purpose of the workshop is to provide a public forum to assess
the emerging research opportunities, potential clinical applications,
and accompanying risks associated with the use of thalidomide. The
meeting is open to researchers, academic and community-based
physicians, nurses, pharmacists, other health care professionals,
industry personnel, patients, and other interested individuals.
The workshop is sponsored by the Office of Rare Diseases, the
Office of Research on Women's Health, the Office of Medical
Applications of Research, the National Institute of Allergy and
Infectious Diseases, the National Institute of Arthritis and
Musculoskeletal and Skin Diseases, the National Institute of Dental
Research, and the National Institute of Child Health and Human
Development of the National Institutes of Health; by the Center for
Drug Evaluation and Research and the Office of Special Health Issues of
the Food and Drug Administration; and by the Centers for Disease
Control and Prevention.
Advance information on the conference program and conference
registration materials may be obtained from Prospect Associates, 1801
Rockville Pike, Suite 500, Rockville, Maryland 20852, (301) 468-MEET;
by e-mail to [email protected]; or at http://
rarediseases.info.nih.gov/ord on the World Wide Web.
Dated August 12, 1997.
Ruth L. Kirschstein,
Deputy Director, National Institutes of Health.
[FR Doc. 97-23383 Filed 9-3-97; 8:45 am]
BILLING CODE 4140-01-M
